{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-chemo-neuropathy","title":"VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review","body":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy damages peripheral nerves through direct toxicity and inflammation. This leads to symptoms like numbness, tingling, burning pain, and reduced sensation, mainly in hands and feet. The damage affects nerve fibers, myelin sheaths, and supporting cells. Repair pathways fall behind degeneration, so symptoms persist after treatment ends.\n\n## Why VIP might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP acts on immune and autonomic layers. In rat sciatic nerve injury models, VIP rises after damage and supports remyelination by acting on Schwann cells while lowering pro-inflammatory signals. If your CIPN involves ongoing inflammation around damaged nerves, this pathway could aid tissue-level repair rather than just quieting symptoms.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It can reduce pain perception but does not address the underlying nerve degeneration or support repair pathways in CIPN. Guidelines note limited or no benefit in this specific condition compared with other neuropathies, so any relief trades off against potential side effects without advancing regeneration.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer of degeneration. Gabapentin / pregabalin addresses symptom signaling only. No direct interaction data exists between them for CIPN.\n\n## What the evidence actually shows\n\nNo human trials test VIP for CIPN. Preclinical work shows VIP in rat peripheral nerve injury models promotes myelin gene expression in Schwann cells and reduces inflammatory cytokines (preclinical). One rat study measured VIP levels rising during regeneration after sciatic crush. No CIPN-specific rat studies exist. No Reddit or X anecdotes link VIP peptide use to CIPN outcomes.\n\n## What scientists say\n\nResearch on VIP focuses on general nerve injury repair in animals. Scientists note its potential paracrine effects on remyelination and inflammation resolution after trauma, but emphasize the gap to clinical CIPN application.\n\n## What people say on Reddit\n\nNo posts describe VIP peptide experiences with chemo neuropathy. Discussions center on standard symptom management or other compounds.\n\n## What people say on X\n\nNo relevant posts discuss VIP for CIPN.\n\n## What we do not know\n\nWhether VIP crosses into meaningful human nerve repair for CIPN remains unknown. Dose, timing, delivery method, and long-term effects lack any data. Interaction with ongoing chemotherapy or gabapentinoids is unstudied.\n\n## Safety and limits\n\nVIP research stays at the animal and mechanistic stage for nerve contexts. No established safety profile exists for this use. Any consideration stays experimental.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-chemo-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials exist testing VIP for CIPN.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Sets baseline that all VIP-CIPN discussion is non-clinical.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In rat sciatic nerve injury models VIP supports remyelination and reduces Schwann cell inflammatory cytokines.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only concrete data layer for VIP nerve repair logic.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"ASCO guidelines do not recommend gabapentin/pregabalin for CIPN prevention or treatment outside trials.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Directly informs the suppression-without-repair framing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01326/full","title":"Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury","quote":"Our results provide evidence that VIP and PACAP could have important functions in the distal nerve stump following injury to promote remyelination and regulate the inflammatory response.","summary":"Rat Schwann cell and nerve injury model showing VIP effects on myelin genes and cytokines.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:04.246Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"db6ffa0c1d42c9ea208cd0ce1fe51f65d659f78e52f175e014b3b49f18f5b714"},{"id":"s2","type":"review","url":"https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/prevention-and-management-of-2020.pdf","title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy","quote":"Outside the context of a clinical trial, no recommendations can be made on the use of ... Gabapentin/pregabalin","summary":"ASCO-aligned guideline summary on CIPN pharmacotherapy limits.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:04.246Z","link_status":"ok","quote_status":"unverified","prev":"db6ffa0c1d42c9ea208cd0ce1fe51f65d659f78e52f175e014b3b49f18f5b714","hash":"49246ffed8f2e787c635e9f2548a780f0072b46dde846f3ca906180dc941cb1b"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:34:08.499Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy damages peripheral nerves through direct toxicity and inflammation. This leads to symptoms like numbness, tingling, burning pain, and reduced sensation, mainly in hands and feet. The damage affects nerve fibers, myelin sheaths, and supporting cells. Repair pathways fall behind degeneration, so symptoms persist after treatment ends.\n\n## Why VIP might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP acts on immune and autonomic layers. In rat sciatic nerve injury models, VIP rises after damage and supports remyelination by acting on Schwann cells while lowering pro-inflammatory signals. If your CIPN involves ongoing inflammation around damaged nerves, this pathway could aid tissue-level repair rather than just quieting symptoms.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It can reduce pain perception but does not address the underlying nerve degeneration or support repair pathways in CIPN. Guidelines note limited or no benefit in this specific condition compared with other neuropathies, so any relief trades off against potential side effects without advancing regeneration.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer of degeneration. Gabapentin / pregabalin addresses symptom signaling only. No direct interaction data exists between them for CIPN.\n\n## What the evidence actually shows\n\nNo human trials test VIP for CIPN. Preclinical work shows VIP in rat peripheral nerve injury models promotes myelin gene expression in Schwann cells and reduces inflammatory cytokines (preclinical). One rat study measured VIP levels rising during regeneration after sciatic crush. No CIPN-specific rat studies exist. No Reddit or X anecdotes link VIP peptide use to CIPN outcomes.\n\n## What scientists say\n\nResearch on VIP focuses on general nerve injury repair in animals. Scientists note its potential paracrine effects on remyelination and inflammation resolution after trauma, but emphasize the gap to clinical CIPN application.\n\n## What people say on Reddit\n\nNo posts describe VIP peptide experiences with chemo neuropathy. Discussions center on standard symptom management or other compounds.\n\n## What people say on X\n\nNo relevant posts discuss VIP for CIPN.\n\n## What we do not know\n\nWhether VIP crosses into meaningful human nerve repair for CIPN remains unknown. Dose, timing, delivery method, and long-term effects lack any data. Interaction with ongoing chemotherapy or gabapentinoids is unstudied.\n\n## Safety and limits\n\nVIP research stays at the animal and mechanistic stage for nerve contexts. No established safety profile exists for this use. Any consideration stays experimental.","claims":[{"id":"c1","text":"No human trials exist testing VIP for CIPN.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Sets baseline that all VIP-CIPN discussion is non-clinical.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In rat sciatic nerve injury models VIP supports remyelination and reduces Schwann cell inflammatory cytokines.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only concrete data layer for VIP nerve repair logic.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"ASCO guidelines do not recommend gabapentin/pregabalin for CIPN prevention or treatment outside trials.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Directly informs the suppression-without-repair framing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01326/full","title":"Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury","quote":"Our results provide evidence that VIP and PACAP could have important functions in the distal nerve stump following injury to promote remyelination and regulate the inflammatory response.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/prevention-and-management-of-2020.pdf","title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy","quote":"Outside the context of a clinical trial, no recommendations can be made on the use of ... Gabapentin/pregabalin","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":28777,"tokens_out":2017,"cost":0.04101375,"prev_hash":"genesis","hash":"9e929fabed0251591e325e27012ac184ff6cc39c085798ba1704774ccbc711ed"}],"provenance":[{"ts":"2026-06-29T22:34:08.499Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Chemo Neuropathy\nSlug: vip-chemo-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Chemotherapy-induced neuropathy (CIPN)\",\"condition_key\":\"chemo-neuropathy\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[\"gabapentin-lyrica\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"gabapentin-lyrica\",\"name\":\"Gabapentin / pregabalin\",\"section_title\":\"Why Gabapentin / pregabalin matters for you\",\"steps\":[\"**Drug:** Gabapentin / pregabalin\",\"**What it does:** Masks neuropathic pain signal; does not repair nerve.\",\"**Therefore for you:** state wheth","response":"{\n  \"slug\": \"vip-chemo-neuropathy\",\n  \"title\": \"VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review\",\n  \"body\": \"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\\n\\nChemotherapy damages peripheral nerves through direct toxicity and inflammation. This leads to symptoms like numbness, tingling, burning pain, and reduced sensation, mainly in hands and feet. The damage affects nerve fibers, myelin sheaths, and supporting cells. Repair pathways fall behind degeneration, so symptoms persist after treatment ends.\\n\\n## Why VIP might help you\\n\\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nVIP acts on immune and autonomic layers. In rat sciatic nerve injury models, VIP rises after damage and supports remyelination by acting on Schwann cells while lowering pro-inflammatory signals. If your CIPN involves ongoing inflammation around damaged nerves, this pathway could aid tissue-level repair rather than just quieting symptoms.\\n\\n## Why Gabapentin / pregabalin matters for you\\n\\n**Drug:** Gabapentin / pregabalin\\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\\n**Therefore for you:** This drug suppresses a signal. It can reduce pain perception but does not address the underlying nerve degeneration or support repair pathways in CIPN. Guidelines note limited or no benefit in this specific condition compared with other neuropathies, so any relief trades off against potential side effects without advancing regeneration.\\n\\n## How these fit together\\n\\nSingle-compound focus — VIP targets the immune / autonomic layer of degeneration. Gabapentin / pregabalin addresses symptom signaling only. No direct interaction data exists between them for CIPN.\\n\\n## What the evidence actually shows\\n\\nNo huma","tokens_in":28777,"tokens_out":2017,"cost":0,"prev":"genesis","hash":"592676b2e49e9a14f4f5c13749aa2b2a37a784f6a33809a7dd4b21a48298251f"},{"ts":"2026-07-17T02:43:22.642Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-chemo-neuropathy","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"592676b2e49e9a14f4f5c13749aa2b2a37a784f6a33809a7dd4b21a48298251f","hash":"8dda038fe01b72de707a1fd8c780b1490bff03d2e0a79378b017f05452bb2981"}],"energy":{"passes":2,"tokens_in":28777,"tokens_out":2017,"tokens_total":30794,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8dda038fe01b72de707a1fd8c780b1490bff03d2e0a79378b017f05452bb2981"},"posted_at":"2026-06-29T21:33:49.062Z","created_at":"2026-06-29T21:33:49.062Z","updated_at":"2026-07-17T02:43:22.642Z","machine":{"shape":"article.machine/v1","slug":"vip-chemo-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-chemo-neuropathy","json":"https://miscsubjects.com/api/articles/vip-chemo-neuropathy","bundle":"https://miscsubjects.com/api/articles/vip-chemo-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":2,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-chemo-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-chemo-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-chemo-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-chemo-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-chemo-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-chemo-neuropathy","json":"/api/articles/vip-chemo-neuropathy","markdown":"/api/articles/vip-chemo-neuropathy/bundle?format=markdown","skill":"/api/articles/vip-chemo-neuropathy/skill","topology":"/api/articles/vip-chemo-neuropathy/topology","versions":"/api/articles/vip-chemo-neuropathy/revisions","invocations":"/api/articles/vip-chemo-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-chemo-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"3b78997c58af479fda4fdaf91ec48037a84b9abd28b59b49a97eb184f4941579","object":{"object_type":"article-object","identity":{"id":"article:vip-chemo-neuropathy","slug":"vip-chemo-neuropathy","title":"VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-chemo-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-chemo-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-chemo-neuropathy\ndescription: Apply the VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-chemo-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-chemo-neuropathy.\n- Read claims and relationships at /api/articles/vip-chemo-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Chemotherapy-induced neuropathy CIPN Chemotherapy damages peripheral nerves through direct toxicity and inflammation. This leads to symptoms like numbness, tingling, burning pain, and reduced sensation, main\n\n## Representations\n\n- Human: /a/vip-chemo-neuropathy\n- JSON: /api/articles/vip-chemo-neuropathy\n- Relationships: /api/articles/vip-chemo-neuropathy/topology\n- History: /api/articles/vip-chemo-neuropathy/revisions\n"},"json":{"route":"/api/articles/vip-chemo-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-chemo-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","chemo","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-chemo-neuropathy/invocations?status=success","failure_events":"/api/articles/vip-chemo-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-chemo-neuropathy","title":"VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review","body":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy damages peripheral nerves through direct toxicity and inflammation. This leads to symptoms like numbness, tingling, burning pain, and reduced sensation, mainly in hands and feet. The damage affects nerve fibers, myelin sheaths, and supporting cells. Repair pathways fall behind degeneration, so symptoms persist after treatment ends.\n\n## Why VIP might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP acts on immune and autonomic layers. In rat sciatic nerve injury models, VIP rises after damage and supports remyelination by acting on Schwann cells while lowering pro-inflammatory signals. If your CIPN involves ongoing inflammation around damaged nerves, this pathway could aid tissue-level repair rather than just quieting symptoms.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It can reduce pain perception but does not address the underlying nerve degeneration or support repair pathways in CIPN. Guidelines note limited or no benefit in this specific condition compared with other neuropathies, so any relief trades off against potential side effects without advancing regeneration.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer of degeneration. Gabapentin / pregabalin addresses symptom signaling only. No direct interaction data exists between them for CIPN.\n\n## What the evidence actually shows\n\nNo human trials test VIP for CIPN. Preclinical work shows VIP in rat peripheral nerve injury models promotes myelin gene expression in Schwann cells and reduces inflammatory cytokines (preclinical). One rat study measured VIP levels rising during regeneration after sciatic crush. No CIPN-specific rat studies exist. No Reddit or X anecdotes link VIP peptide use to CIPN outcomes.\n\n## What scientists say\n\nResearch on VIP focuses on general nerve injury repair in animals. Scientists note its potential paracrine effects on remyelination and inflammation resolution after trauma, but emphasize the gap to clinical CIPN application.\n\n## What people say on Reddit\n\nNo posts describe VIP peptide experiences with chemo neuropathy. Discussions center on standard symptom management or other compounds.\n\n## What people say on X\n\nNo relevant posts discuss VIP for CIPN.\n\n## What we do not know\n\nWhether VIP crosses into meaningful human nerve repair for CIPN remains unknown. Dose, timing, delivery method, and long-term effects lack any data. Interaction with ongoing chemotherapy or gabapentinoids is unstudied.\n\n## Safety and limits\n\nVIP research stays at the animal and mechanistic stage for nerve contexts. No established safety profile exists for this use. Any consideration stays experimental.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-chemo-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human trials exist testing VIP for CIPN.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Sets baseline that all VIP-CIPN discussion is non-clinical.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In rat sciatic nerve injury models VIP supports remyelination and reduces Schwann cell inflammatory cytokines.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only concrete data layer for VIP nerve repair logic.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"ASCO guidelines do not recommend gabapentin/pregabalin for CIPN prevention or treatment outside trials.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Directly informs the suppression-without-repair framing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01326/full","title":"Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury","quote":"Our results provide evidence that VIP and PACAP could have important functions in the distal nerve stump following injury to promote remyelination and regulate the inflammatory response.","summary":"Rat Schwann cell and nerve injury model showing VIP effects on myelin genes and cytokines.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:04.246Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"db6ffa0c1d42c9ea208cd0ce1fe51f65d659f78e52f175e014b3b49f18f5b714"},{"id":"s2","type":"review","url":"https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/prevention-and-management-of-2020.pdf","title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy","quote":"Outside the context of a clinical trial, no recommendations can be made on the use of ... Gabapentin/pregabalin","summary":"ASCO-aligned guideline summary on CIPN pharmacotherapy limits.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:34:04.246Z","link_status":"ok","quote_status":"unverified","prev":"db6ffa0c1d42c9ea208cd0ce1fe51f65d659f78e52f175e014b3b49f18f5b714","hash":"49246ffed8f2e787c635e9f2548a780f0072b46dde846f3ca906180dc941cb1b"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:34:08.499Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy damages peripheral nerves through direct toxicity and inflammation. This leads to symptoms like numbness, tingling, burning pain, and reduced sensation, mainly in hands and feet. The damage affects nerve fibers, myelin sheaths, and supporting cells. Repair pathways fall behind degeneration, so symptoms persist after treatment ends.\n\n## Why VIP might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP acts on immune and autonomic layers. In rat sciatic nerve injury models, VIP rises after damage and supports remyelination by acting on Schwann cells while lowering pro-inflammatory signals. If your CIPN involves ongoing inflammation around damaged nerves, this pathway could aid tissue-level repair rather than just quieting symptoms.\n\n## Why Gabapentin / pregabalin matters for you\n\n**Drug:** Gabapentin / pregabalin\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\n**Therefore for you:** This drug suppresses a signal. It can reduce pain perception but does not address the underlying nerve degeneration or support repair pathways in CIPN. Guidelines note limited or no benefit in this specific condition compared with other neuropathies, so any relief trades off against potential side effects without advancing regeneration.\n\n## How these fit together\n\nSingle-compound focus — VIP targets the immune / autonomic layer of degeneration. Gabapentin / pregabalin addresses symptom signaling only. No direct interaction data exists between them for CIPN.\n\n## What the evidence actually shows\n\nNo human trials test VIP for CIPN. Preclinical work shows VIP in rat peripheral nerve injury models promotes myelin gene expression in Schwann cells and reduces inflammatory cytokines (preclinical). One rat study measured VIP levels rising during regeneration after sciatic crush. No CIPN-specific rat studies exist. No Reddit or X anecdotes link VIP peptide use to CIPN outcomes.\n\n## What scientists say\n\nResearch on VIP focuses on general nerve injury repair in animals. Scientists note its potential paracrine effects on remyelination and inflammation resolution after trauma, but emphasize the gap to clinical CIPN application.\n\n## What people say on Reddit\n\nNo posts describe VIP peptide experiences with chemo neuropathy. Discussions center on standard symptom management or other compounds.\n\n## What people say on X\n\nNo relevant posts discuss VIP for CIPN.\n\n## What we do not know\n\nWhether VIP crosses into meaningful human nerve repair for CIPN remains unknown. Dose, timing, delivery method, and long-term effects lack any data. Interaction with ongoing chemotherapy or gabapentinoids is unstudied.\n\n## Safety and limits\n\nVIP research stays at the animal and mechanistic stage for nerve contexts. No established safety profile exists for this use. Any consideration stays experimental.","claims":[{"id":"c1","text":"No human trials exist testing VIP for CIPN.","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Sets baseline that all VIP-CIPN discussion is non-clinical.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In rat sciatic nerve injury models VIP supports remyelination and reduces Schwann cell inflammatory cytokines.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the only concrete data layer for VIP nerve repair logic.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"ASCO guidelines do not recommend gabapentin/pregabalin for CIPN prevention or treatment outside trials.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Directly informs the suppression-without-repair framing.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:34:07.970Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01326/full","title":"Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury","quote":"Our results provide evidence that VIP and PACAP could have important functions in the distal nerve stump following injury to promote remyelination and regulate the inflammatory response.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/prevention-and-management-of-2020.pdf","title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy","quote":"Outside the context of a clinical trial, no recommendations can be made on the use of ... Gabapentin/pregabalin","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":28777,"tokens_out":2017,"cost":0.04101375,"prev_hash":"genesis","hash":"9e929fabed0251591e325e27012ac184ff6cc39c085798ba1704774ccbc711ed"}],"provenance":[{"ts":"2026-06-29T22:34:08.499Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Chemo Neuropathy\nSlug: vip-chemo-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Chemotherapy-induced neuropathy (CIPN)\",\"condition_key\":\"chemo-neuropathy\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[\"gabapentin-lyrica\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"gabapentin-lyrica\",\"name\":\"Gabapentin / pregabalin\",\"section_title\":\"Why Gabapentin / pregabalin matters for you\",\"steps\":[\"**Drug:** Gabapentin / pregabalin\",\"**What it does:** Masks neuropathic pain signal; does not repair nerve.\",\"**Therefore for you:** state wheth","response":"{\n  \"slug\": \"vip-chemo-neuropathy\",\n  \"title\": \"VIP for Chemotherapy-Induced Neuropathy: A Data-First Evidence Review\",\n  \"body\": \"## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\\n\\nChemotherapy damages peripheral nerves through direct toxicity and inflammation. This leads to symptoms like numbness, tingling, burning pain, and reduced sensation, mainly in hands and feet. The damage affects nerve fibers, myelin sheaths, and supporting cells. Repair pathways fall behind degeneration, so symptoms persist after treatment ends.\\n\\n## Why VIP might help you\\n\\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nVIP acts on immune and autonomic layers. In rat sciatic nerve injury models, VIP rises after damage and supports remyelination by acting on Schwann cells while lowering pro-inflammatory signals. If your CIPN involves ongoing inflammation around damaged nerves, this pathway could aid tissue-level repair rather than just quieting symptoms.\\n\\n## Why Gabapentin / pregabalin matters for you\\n\\n**Drug:** Gabapentin / pregabalin\\n**What it does:** Masks neuropathic pain signal; does not repair nerve.\\n**Therefore for you:** This drug suppresses a signal. It can reduce pain perception but does not address the underlying nerve degeneration or support repair pathways in CIPN. Guidelines note limited or no benefit in this specific condition compared with other neuropathies, so any relief trades off against potential side effects without advancing regeneration.\\n\\n## How these fit together\\n\\nSingle-compound focus — VIP targets the immune / autonomic layer of degeneration. Gabapentin / pregabalin addresses symptom signaling only. No direct interaction data exists between them for CIPN.\\n\\n## What the evidence actually shows\\n\\nNo huma","tokens_in":28777,"tokens_out":2017,"cost":0,"prev":"genesis","hash":"592676b2e49e9a14f4f5c13749aa2b2a37a784f6a33809a7dd4b21a48298251f"},{"ts":"2026-07-17T02:43:22.642Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-chemo-neuropathy","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"592676b2e49e9a14f4f5c13749aa2b2a37a784f6a33809a7dd4b21a48298251f","hash":"8dda038fe01b72de707a1fd8c780b1490bff03d2e0a79378b017f05452bb2981"}],"energy":{"passes":2,"tokens_in":28777,"tokens_out":2017,"tokens_total":30794,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8dda038fe01b72de707a1fd8c780b1490bff03d2e0a79378b017f05452bb2981"},"posted_at":"2026-06-29T21:33:49.062Z","created_at":"2026-06-29T21:33:49.062Z","updated_at":"2026-07-17T02:43:22.642Z","machine":{"shape":"article.machine/v1","slug":"vip-chemo-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-chemo-neuropathy","json":"https://miscsubjects.com/api/articles/vip-chemo-neuropathy","bundle":"https://miscsubjects.com/api/articles/vip-chemo-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":2,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-chemo-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-chemo-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-chemo-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-chemo-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-chemo-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-chemo-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-chemo-neuropathy","json":"/api/articles/vip-chemo-neuropathy","markdown":"/api/articles/vip-chemo-neuropathy/bundle?format=markdown","skill":"/api/articles/vip-chemo-neuropathy/skill","topology":"/api/articles/vip-chemo-neuropathy/topology","versions":"/api/articles/vip-chemo-neuropathy/revisions","invocations":"/api/articles/vip-chemo-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-chemo-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"3b78997c58af479fda4fdaf91ec48037a84b9abd28b59b49a97eb184f4941579"}}}